Synthetic Lab Data Generation Market Report 2026

The synthetic lab data generation market size has grown exponentially in recent years. It will grow from $1.99 billion in 2025 to $2.61 billion in 2026 at a compound annual growth rate (CAGR) of 31.6%. The growth in the historic period can be attributed to early adoption of rule-based data simulators, limited access to real clinical or lab datasets, rising compliance pressure around patient privacy, cost constraints in manual data collection processes, and academic demand for controlled benchmark datasets.

The synthetic lab data generation market size is expected to see exponential growth in the next few years. It will grow to $7.8 billion in 2030 at a compound annual growth rate (CAGR) of 31.4%. The growth in the forecast period can be attributed to advancements in generative ai architectures for structured scientific data, increasing investment in digital twins for laboratory environments, regulatory encouragement of privacy-preserving data generation, expansion of automated lab robotics requiring synthetic test inputs, and commercial push for scalable r&d simulation platforms. Major trends in the forecast period include integration of synthetic data into lab information management systems, growth of hybrid datasets combining real and synthetic lab outputs, adoption of quality-scoring frameworks for synthetic lab datasets, rising use of multimodal lab data generators, and partnerships between biotech firms and ai vendors for synthetic data solutions.

The rising adoption of AI-powered decision-making tools is expected to drive the growth of the synthetic lab data generation market. AI-powered decision-making tools are software systems that utilize artificial intelligence, such as machine learning and predictive analytics, to automate and enhance business decisions and insights. The increase in adoption is driven by growing enterprise digitalization and the demand for data-driven strategic decision-making. Synthetic lab data generation supports the adoption of AI-powered decision-making tools by providing high-quality, privacy-preserving datasets, enabling faster and more accurate model training. It reduces reliance on scarce or sensitive real-world lab data, improving the efficiency and reliability of AI-driven insights in healthcare, research, and laboratory operations. For example, in January 2025, Eurostat, a Luxembourg-based statistical office of the European Union, reported that in 2024, 13.5% of enterprises with 10 or more employees used AI technologies, up from 8% in 2023, marking a 5.5 percentage-point increase. Therefore, the growing adoption of AI-powered decision-making tools is driving the growth of the synthetic lab data generation market.

The increasing volume of unstructured data from the Internet of Things (IoT) is expected to boost the growth of the synthetic test data generation market. This refers to the expanding amount of schema-less outputs, such as sensor logs, telemetry data, images, and free-form device signals, continuously generated by IoT systems. This volume is growing as global broadband usage surges, driven by an increasing number of connected devices producing high-velocity data streams. Synthetic test data generation enhances AI and analytics capabilities by leveraging the growing unstructured data volume from IoT. It allows organizations to generate realistic, privacy-preserving datasets from sensor logs, telemetry, images, and device signals, improving testing, validation, and decision-making for IoT-scale systems. For example, in May 2025, the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental body, reported that the average monthly data usage per mobile broadband subscription in OECD countries surged by 65% in one year and more than doubled over two years, increasing from 8 GB in June 2022 to 17 GB by June 2024. Therefore, the rising volume of unstructured data from IoT is driving the growth of the synthetic test data generation market.

In March 2025, NVIDIA Corporation, a US-based provider of hardware and AI developer platforms, acquired Gretel.ai Inc. for an undisclosed amount. Through this acquisition, NVIDIA aims to enhance its synthetic-data engine capabilities for developer workflows, enabling scalable synthetic dataset generation and privacy-enhanced pipelines for training and testing. Gretel.ai Inc., a US-based software company, specializes in synthetic data generation for AI, analytics, and privacy-preserving applications.

Major companies operating in the synthetic lab data generation market are Amazon Web Services Inc., Databricks Inc., Owkin Inc., Insilico Medicine Inc., K2View Data Management Ltd., Recursion Pharmaceuticals Inc., Ultromics Ltd., Parallel Domain Inc., Arzeda Corp., PostEra Inc., Sky Engine AI Ltd., MDClone Ltd., Synthesized Ltd., Mostly AI GmbH, Nabla Bio Inc., Rendered.ai Inc., GenRocket Inc., Anyverse Inc., Syntegra Private Limited, Synthetrial Inc.

North America was the largest region in the synthetic lab data generation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the synthetic lab data generation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the synthetic lab data generation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have had a limited but noticeable impact on the synthetic lab data generation market by increasing costs for imported computing hardware, data center infrastructure, and specialized software tools used in on-premises deployments. The effects are more visible in hardware-dependent segments and in regions reliant on cross-border technology trade, particularly Asia-Pacific and parts of Europe. Cloud-based and software-centric solutions face lower exposure, encouraging vendors to prioritize cloud deployment and subscription models. In some cases, tariffs have indirectly accelerated localization of infrastructure and strengthened demand for virtualized, cloud-native synthetic data platforms.

Synthetic lab data generation refers to the creation of artificial, statistically accurate laboratory datasets using advanced AI/ML models such as generative adversarial networks (GANs), variational autoencoders (VAEs), and large language models (LLMs). These datasets replicate real experimental, clinical, toxicological, chemical, and biological data while protecting sensitive information. The primary goal is to enable safe data sharing, accelerate research and development workflows, support model training, and reduce reliance on costly or privacy-sensitive real-world laboratory data. It enhances research efficiency, supports regulatory compliance, and fosters innovation in life sciences.

The main components of synthetic lab data generation include software and services. Software refers to programs and applications that perform specific tasks, automate processes, and provide solutions for users across various industries and research areas. These systems are deployed through on-premises or cloud environments and generate synthetic clinical, genomic, imaging, laboratory test, and other data types for secure and scalable use. Key applications include healthcare research, drug discovery, diagnostics, and medical training, with end-users including pharmaceutical and biotechnology companies, hospitals and clinics, academic and research institutes, and others.

The synthetic lab data generation market consists of revenues earned by entities that provide solutions such as synthetic data generation platforms, laboratory data simulation tools, AI-based modeling engines, privacy-preserving data pipelines, and validation frameworks. The market value includes related services such as dataset customization, domain-specific modeling, data quality evaluation, and integration with laboratory information systems (LIS/LIMS). It also includes sales of supporting software components and tools used for generating tabular, time-series, imaging, and molecular datasets. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators of the tools - whether to other organizations (LIMS vendors, CROs, pharma companies, healthcare institutions) or directly to end users. The value includes associated services provided by the creators of these solutions.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.